KRAS and RYR2 mutations significantly predict unresectable recurrence

The study identified several key prognostic factors impacting unresectable recurrence-free survival (urfs) in colorectal liver-only metastasis patients. Significant predictors included KRAS G12D mutation positivity (HR: 7.69), RYR2 mutation positivity (HR: 4.03), KRAS G12S mutation positivity (HR: 3.96), CA19-9 > 37 U/ml prior to hepatectomy (HR: 3.62), and primary tumor PN2 stage (HR: 3.22). These findings underscore the importance of specific mutations in shaping patient outcomes.